Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Johnson and Johnson
Boehringer Ingelheim
AstraZeneca
Colorcon

Last Updated: October 17, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR IMIPENEM AND CILASTATIN

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Imipenem And Cilastatin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00080496 Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 2003-07-01 To compare the efficacy and safety of the tigecycline regimen with that of the imipenem/cilastatin regimen in subjects with nosocomial pneumonia.
NCT00081744 Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized Subjects Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 2002-11-01 Purpose: To provide a mechanism for the emergency use of tigecycline in the appropriate clinical situations.
NCT00136201 Study Comparing Tigecycline and Imipenem/Cilastatin in Chinese Subjects With Complicated Intra-Abdominal Infections Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 2005-11-01 The primary objective of this study is to compare the safety and efficacy of an experimental antibiotic to a marketed antibiotic in the treatment of Chinese subjects with complicated intra-abdominal infections.
NCT00236834 A Study of the Safety and Effectiveness of Levofloxacin Compared With Imipenem/Cilastatin in Patients With Pneumonia Acquired During Hospitalization Completed PriCara, Unit of Ortho-McNeil, Inc. Phase 3 1997-12-01 The purpose of this study is to compare the safety and effectiveness of levofloxacin with imipenem/cilastatin in the treatment of hospital-acquired pneumonia
NCT00236834 A Study of the Safety and Effectiveness of Levofloxacin Compared With Imipenem/Cilastatin in Patients With Pneumonia Acquired During Hospitalization Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 3 1997-12-01 The purpose of this study is to compare the safety and effectiveness of levofloxacin with imipenem/cilastatin in the treatment of hospital-acquired pneumonia
NCT00515034 A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 2 2007-10-01 The purpose of this study is to assess the safety and tolerability of doripenem compared to imipenem in Ventilator-assisted pneumonia and complicated Intra-abdominal Infection. The study population will include hospitalized patients (or patients resident in a chronic health care facility) who have a diagnosis of either Ventilator associated pneumonia or complicated Intra-abdominal Infection.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Imipenem And Cilastatin

Condition Name

Condition Name for Imipenem And Cilastatin
Intervention Trials
Urinary Tract Infections 3
Bacterial Infections 2
Pneumonia, Bacterial 2
Complicated Urinary Tract Infection 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Imipenem And Cilastatin
Intervention Trials
Infection 17
Communicable Diseases 15
Pneumonia 7
Intraabdominal Infections 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Imipenem And Cilastatin

Trials by Country

Trials by Country for Imipenem And Cilastatin
Location Trials
United States 49
China 29
France 6
Argentina 6
Brazil 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Imipenem And Cilastatin
Location Trials
California 4
Ohio 4
Illinois 3
Michigan 2
North Carolina 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Imipenem And Cilastatin

Clinical Trial Phase

Clinical Trial Phase for Imipenem And Cilastatin
Clinical Trial Phase Trials
Phase 4 5
Phase 3 12
Phase 2/Phase 3 1
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Imipenem And Cilastatin
Clinical Trial Phase Trials
Completed 12
Recruiting 8
Not yet recruiting 4
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Imipenem And Cilastatin

Sponsor Name

Sponsor Name for Imipenem And Cilastatin
Sponsor Trials
Merck Sharp & Dohme Corp. 11
Wyeth is now a wholly owned subsidiary of Pfizer 3
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Imipenem And Cilastatin
Sponsor Trials
Industry 26
Other 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
McKinsey
Colorcon
McKesson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.